Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis

AcelRx Pharmaceuticals logo

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.49
$0.86
52-Week Range
N/A
Volume
243,500 shs
Average Volume
137,683 shs
Market Capitalization
$14.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

Why Buffett and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
See More Headlines

ACRX Stock Analysis - Frequently Asked Questions

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) EPS for the quarter, hitting analysts' consensus estimates of ($1.40). The specialty pharmaceutical company earned $1.86 million during the quarter, compared to the consensus estimate of $1.20 million.

AcelRx Pharmaceuticals's stock reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/15/2021
Today
2/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACRX
Employees
19
Year Founded
N/A

Profitability

Net Income
$47.76 million
Pretax Margin
-3,711.25%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$2.65 per share

Miscellaneous

Free Float
16,443,000
Market Cap
$14.58 million
Optionable
Optionable
Beta
0.52

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ACRX) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners